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The white paper on public health
Is promising, but has some blind spots, which must be tackled
The white paper Choosing Health: making healthychoices easier lays out the government’s approachto tackling a broad range of public health
challenges from smoking, obesity, and drinking to men-
tal and sexual health.1 Positive aspects, such as signpost-
ing foods to indicate their fat, salt, and sugar contents
have quite rightly been welcomed. Limitations, including
the ironic coupling of the emphasis on individual choice
with a failure to tackle secondhand smoke, are being
highlighted by the relevant expert groups. The public
are developing an awareness of the relevance of these
public health issues in their lives, thanks in part to the
substantial media coverage of the report’s contents and
of stakeholders’ responses. At least these problems are
beginning to get a thorough public airing, which must
be a step in the right direction for further policy change.
However, to maximise the benefits of such a substantial
switch towards prevention, as urged by Wanless,2 three
fundamental blind spots need to be considered.
The first exemplifies a historical failure to match
rhetoric with action. The report promises to help local
health services deal with inequalities: “We are giving
primary care trusts the means to tackle health
inequalities and improve health through funding to
give greater priority to areas of high health need . . .”
This implies recognition of the need to provide greater
resources to those primary care trusts in most need in
order to move disadvantaged people up to the level of
advantaged people.3 However, the promise rings
hollow for many primary care trusts serving deprived
communities. The government has set inequalities tar-
gets for these primary care trusts requiring them to
improve the health of their populations faster than the
average for the United Kingdom.4 Many of these are
already struggling because they have not even received
the funding they are due according to the govern-
ment’s own calculations of their requirements.5 In
northeast London, for example, all four of the primary
care trusts defined as being in the government’s
“spearhead group” (which means they have the worst
health and deprivation indices), are currently under-
funded to a total of over £80m ($149m; €114m) against
their weighted capitation target.
The second blind spot is an inability to work
through the consequences of worrying about being
labelled as a nanny state. As a result, the recommenda-
tions on banning smoking are inconsistent and may
actually increase health inequalities due to differential
uptake by people across the socioeconomic divide.6
Encouraging smoking cessation on an individual level
is one thing, but allowing smoking in pubs that do not
serve prepared food undermines this effort. It is
precisely people who visit pubs where food is not
served who are in most need of protection from the
effects of secondhand smoke. In this way the white
paper fails to address the inequalities that purport to
be the driving force behind it.
The third blind spot is the government’s reluctance
to take its own medicine. That decisions should be
informed by robust research evidence is becoming
embedded across the health service, and the white paper
does pay some attention to the need to use evidence
based interventions. A pity then that such emphasis is
placed on individualistic interventions such as the provi-
sion of educational materials, when it is well established
that information alone does not entice people to change
behaviour. Nor will the provision of fruit for your lunch
box alter eating habits so long as healthy eating is
perceived to be posh.7 That the government persists in
believing that it is as simple as that is disappointing.
Improving public health is about changing behaviour.
We need an in-depth understanding of the personal val-
ues, beliefs, preferences, and aspirations that drive
behaviours in different social groups. Only then can we
begin to design interventions to modify deep seated cul-
tural norms and to challenge ingrained ambivalence.
Changing behaviour will require the implementation of
comprehensive structural, environmental, and eco-
nomic interventions. For example, the report has
nothing about using the taxation system to increase the
minimum weekly income for healthy living,8 or for
increasing taxes on tobacco, which are known to have
the greatest effects on smoking levels of young people.9
The white paper does signal a seminal moment in
terms of attention to public health and could have a
profound impact. But the government must consider
its blind spots and show a commitment to tackle com-
plex environmental and personal barriers to behaviour
change if it is to fulfil its pledge to make healthy
choices easier.
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Angiotensin receptor blockers and myocardial
infarction
These drugs may increase myocardial infarction—and patients may need to be told
The interpretation of large scale clinical trials isbeing increasingly scrutinised by leadingjournals,1 with great emphasis being placed on
the importance of sharing all potential side effects, no
matter how trivial, with patients. The Lancet recently
published the results of the valsartan antihypertensive
long term use evaluation (VALUE) trial, a study of the
effects of reducing blood pressure in patients at high
risk.2 The angiotensin receptor blocker valsartan
produced a statistically significant 19% relative
increase in the prespecified secondary end point of
myocardial infarction (fatal and non-fatal) compared
with amlodipine. A doctor who is a patient of one of
the authors (SV) commented that if the incidence of
myocardial infarction increased with valsartan it would
be an essential component of informed consent to
share this information when prescribing valsartan for
high risk patients with high blood pressure. These
peculiar results led us to examine carefully the
evidence surrounding angiotensin receptor blocker
and myocardial infarction.
Could the unexpected increase in the incidence of
myocardial infarction in the VALUE trial represent a
statistical aberration? Although the modest, yet signifi-
cant differential in blood pressure in favour of
amlodipine (1.8 mmHg systolic and 1.5 mmHg diastolic
v amlodipine) may explain the 13% increase in the
incidence of stroke in patients taking valsartan (P = 0.08),
it is unlikely, according to some experts, to account for the
19% increase in the incidence of myocardial infarction.3
Unfortunately careful evaluation of the current evi-
dence shows that angiotensin receptor blockers, unlike
angiotensin converting enzyme inhibitors, are either
neutral or increase the rates of myocardial infarction
despite their beneficial effects on reducing blood
pressure.
For example, the CHARM-alternative trial showed a
significant 36% increase in myocardial infarction with
candesartan (versus placebo) despite a reduction in
blood pressure (4.4 mm Hg systolic and 3.9 mm Hg
diastolic v placebo treatment).4 Likewise, in the
CHARM-preserved study, candesartan reduced admis-
sions for chronic heart failure by 13% but did not
prevent death despite a mortality of 11.3% and a reduc-
tion in blood pressure of 7 mm Hg systolic and
3 mm Hg diastolic compared with placebo.5 In the study
on cognition and prognosis in the elderly (SCOPE), can-
desartan was associated with a non-significant 10%
increase in fatal plus non-fatal myocardial infarction
despite lower blood pressure (3.2 mm Hg systolic and
1.6 mm Hg diastolic for candesartan v placebo).6
Furthermore, the angiotensin receptor blocker losartan
in the LIFE study did not reduce rates of myocardial inf-
arction despite a 1.7 mm Hg lower pulse pressure com-
pared with atenolol.7 In the RENAAL trial, a study
performed in diabetic patients with nephropathy, the
angiotensin receptor blocker losartan offered nephro-
protection, but no reduction in cardiovascular mortality,
although about 30% of patients died of a cardiovascular
event.8 In a similar population the angiotensin receptor
blocker irbesartan showed nephroprotection9 but
seemed to have no impact on the 24% incidence of car-
diovascular events (a secondary composite end point).
Although irbesartan lowered blood pressure (4 mm Hg
systolic and 3 mm Hg diastolic v placebo), no reduction
occurred in myocardial infarction, stroke, or cardiovas-
cular death. Compared with amlodipine, irbesartan was
associated with a 36% increase in non-fatal myocardial
infarction (P = 0.06), a 48% non-significant increase in
stroke, and a 29% non-significant increase in death
despite similar blood pressure reduction (see advisory
briefing of the Food and Drug Administration, NDA
20-757 (S-021), www.fda.gov).
These peculiar effects of angiotensin receptor
blockers on myocardial infarction stand in contrast to
those of angiotensin converting enzyme inhibitors,
which consistently produce a 20% or greater reduction
in myocardial infarction in patients with diabetes,
hypertension, renal insufficiency, and atherosclerosis.
How could two pharmacological agents, considered
by many to be interchangeable and equivalent, have
such divergent effects on coronary vascular outcomes
despite similar effects on blood pressure? Medicine con-
tains several examples of similar pharmacological
conundrums. For example,metformin and phenformin,
agents of the same class that have similar effects on insu-
lin sensitivity and glycaemic control, have different side
effects, and phenformin is associated with a higher rate
of lactic acidosis. Troglitazone, rosiglitazone, and piogli-
tazone are all thiazolidinedione insulin sensitisers, yet
troglitazone was removed from the market because of
increased rates of hepatocellular necrosis. Different
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